

# Giuseppe Cicero

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4654025/publications.pdf>

Version: 2024-02-01

51  
papers

1,906  
citations

331538

21  
h-index

254106

43  
g-index

52  
all docs

52  
docs citations

52  
times ranked

3446  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting Human $\gamma\delta$ T Cells with Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer. <i>Cancer Research</i> , 2007, 67, 7450-7457.	0.4	443
2	Characterization of Human $\gamma\delta$ T Lymphocytes Infiltrating Primary Malignant Melanomas. <i>PLoS ONE</i> , 2012, 7, e49878.	1.1	137
3	PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. <i>Oncotarget</i> , 2016, 7, 19738-19747.	0.8	134
4	The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S103-S109.	1.5	117
5	Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. <i>Oncotarget</i> , 2016, 7, 60712-60722.	0.8	103
6	Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?. <i>Analytical Cellular Pathology</i> , 2015, 2015, 1-19.	0.7	80
7	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. <i>Oncotarget</i> , 2015, 6, 24780-24796.	0.8	77
8	Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 300-313.	2.0	68
9	Geldanamycin and its derivatives as Hsp90 inhibitors. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 2269.	3.0	64
10	Co-expression of CD133 <sup>+</sup> /CD44 <sup>+</sup> in human colon cancer and liver metastasis. <i>Journal of Cellular Physiology</i> , 2013, 228, 408-415.	2.0	45
11	Germline copy number variation in the <i>YTHDC2</i> gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susceptibility?. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 841-850.	1.5	44
12	Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 1249-1261.	1.5	41
13	Chemotherapy Sensitizes Colon Cancer Initiating Cells to $\gamma\delta$ T Cell-Mediated Cytotoxicity. <i>PLoS ONE</i> , 2013, 8, e65145.	1.1	41
14	Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment. <i>Current Cancer Drug Targets</i> , 2010, 10, 55-67.	0.8	37
15	Primary Non-Hodgkins lymphoma of the parotid gland. <i>Brazilian Journal of Otorhinolaryngology</i> , 2011, 77, 639-644.	0.4	32
16	Hypoxia and Human Genome Stability: Downregulation of BRCA2 Expression in Breast Cancer Cell Lines. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	32
17	The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population. <i>Oncology</i> , 2014, 86, 16-21.	0.9	30
18	Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 563-568.	1.1	29

#	ARTICLE	IF	CITATIONS
19	Effects of PPAR $\alpha$ agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. <i>Journal of Cellular Physiology</i> , 2013, 228, 1368-1374.	2.0	29
20	HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 505-517.	1.1	29
21	Aminobisphosphonates as New Weapons for $\gamma$ ; $\delta$ ; T Cell-Based Immunotherapy of Cancer. <i>Current Medicinal Chemistry</i> , 2008, 15, 1147-1153.	1.2	27
22	Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1553-1566.	1.4	22
23	Characterization of $\gamma$ T Cells in Intestinal Mucosa From Patients With Early-Onset or Long-Standing Inflammatory Bowel Disease and Their Correlation With Clinical Status. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 873-883.	0.6	22
24	Monoclonal antibodies in gastrointestinal cancers. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 889-900.	1.4	18
25	A headlight on liquid biopsies: a challenging tool for breast cancer management. <i>Tumor Biology</i> , 2016, 37, 4263-4273.	0.8	18
26	The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience. <i>Oncology</i> , 2018, 94, 161-166.	0.9	17
27	Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1769-1775.	2.0	17
28	Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1571-1586.	1.5	16
29	Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations. <i>Oncology</i> , 2013, 85, 306-311.	0.9	15
30	Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3059-3063.	1.0	13
31	$\gamma$ ; Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life $\delta$ ; OncoTargets and Therapy, 2019, Volume 12, 1621-1627.	1.0	12
32	Zoledronic Acid Induces a Significant Decrease of Circulating Endothelial Cells and Circulating Endothelial Precursor Cells in the Early Prostate Cancer Neoadjuvant Setting. <i>Oncology</i> , 2013, 85, 342-347.	0.9	11
33	The gene expression profile of cumulus cells reveals altered pathways in patients with endometriosis. <i>Journal of Assisted Reproduction and Genetics</i> , 2014, 31, 1277-1285.	1.2	10
34	The Role of Couples' Attachment Styles in Patients' Adjustment to Cancer. <i>Oncology</i> , 2017, 92, 325-334.	0.9	10
35	Well-Being among Italian Medical Oncologists: An Exploratory Study. <i>Oncology</i> , 2014, 86, 72-78.	0.9	9
36	The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study. <i>Anticancer Research</i> , 2017, 37, 1475-1480.	0.5	9

#	ARTICLE	IF	CITATIONS
37	Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study. <i>Oncology</i> , 2017, 92, 94-100.	0.9	7
38	Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 103-114.	1.4	6
39	Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel. <i>Anti-Cancer Drugs</i> , 2017, 28, 1047-1052.	0.7	6
40	Efficacy and Safety of the Oral Multikinase Regorafenib in Metastatic Colorectal Cancer. <i>Oncology</i> , 2017, 93, 354-358.	0.9	6
41	TAS-102 in metastatic colorectal cancer (mCRC): efficacy, tolerability, and quality of life in heavily pretreated elderly patients: a real-life study. <i>Drugs in Context</i> , 2020, 9, 1-8.	1.0	6
42	Farletuzumab for NSCLC: exploiting a well-known metabolic pathway for a new therapeutic strategy. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 125-132.	1.9	5
43	Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. <i>Journal of Geriatric Oncology</i> , 2022, 13, 302-307.	0.5	4
44	Biomarkers as Prognostic, Predictive, and Surrogate Endpoints. <i>Current Clinical Pathology</i> , 2015, , 31-41.	0.0	2
45	Role of Densitometric Criteria in Evaluation of Effectiveness of Antiangiogenic Therapies in Metastatic Colorectal Cancer: An Italian Clinical Experience. <i>Anticancer Research</i> , 2017, 37, 5187-5192.	0.5	2
46	V $\beta$ 9V $\alpha$ 2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies. <i>Oncology Reviews</i> , 2010, 4, 211-218.	0.8	1
47	Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy. <i>Urology Annals</i> , 2015, 7, 21.	0.3	1
48	Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab). <i>World Journal of Oncology</i> , 2021, 12, 104-110.	0.6	1
49	Vinflunine in Metastatic Urothelial Carcinoma of the Bladder in Progression after a Platinum-Containing Regimen. <i>Oncology</i> , 2019, 97, 341-347.	0.9	0
50	KRAS and BRAF as prognostic biomarkers in patients undergoing surgical resection of colorectal cancer liver metastasis: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3565-3565.	0.8	0
51	Effects of erybuline/capecitabine (EC) treatment in very elderly women (VEW) with MBC.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12508-e12508.	0.8	0